Parathyroid Hormone (1-34)-Coated Microneedle Patch System: Clinical Pharmacokinetics and Pharmacodynamics for Treatment of Osteoporosis

[1] Cormier M(2004)Transdermal delivery of desmopressin using a coated microneedle array patch system J Control Release 97 503-11

[2] Johnson B(2002)Macroflux® microprojection array patch technology: a new and efficient approach for intracutaneous immunization Pharm Res 19 63-70

[3] Ameri M(2006)Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system Vaccine 24 1653-64

[4] Nyam K(2002)Macroflux® transdermal technology development for the delivery of therapeutic peptides and proteins Drug Delivery Technology 2 54-7

[5] Libiran L(2004)Macroflux® desmopressin transdermal delivery system: pharmacokinetics and pharmacodynamic evaluation in healthy volunteers AAPS J 6 665-41

[6] Zhang DD(2009)Erythropoietin (EPO) coated microprojection transdermal system: pre-clinical formulation, stability and delivery AAPS J 11 T2245-501

[7] Matriano JA(2001)Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434-35

[8] Cormier M(2008)Parathyroid hormone treatment of osteoporosis Curr Opin Endocrinol Diab Obes 15 495-44

[9] Johnson J(2006)Patient treatment preferences for osteoporosis Arthritis Rheum 5 729-43

[10] Young WA(2007)Patient willingness to take teriparatide Patient Educ Couns 65 237-9

[1] Cormier M(2004)Transdermal delivery of desmopressin using a coated microneedle array patch system J Control Release 97 503-11

[2] Johnson B(2002)Macroflux® microprojection array patch technology: a new and efficient approach for intracutaneous immunization Pharm Res 19 63-70

[3] Ameri M(2006)Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system Vaccine 24 1653-64

[4] Nyam K(2002)Macroflux® transdermal technology development for the delivery of therapeutic peptides and proteins Drug Delivery Technology 2 54-7

[5] Libiran L(2004)Macroflux® desmopressin transdermal delivery system: pharmacokinetics and pharmacodynamic evaluation in healthy volunteers AAPS J 6 665-41

[6] Zhang DD(2009)Erythropoietin (EPO) coated microprojection transdermal system: pre-clinical formulation, stability and delivery AAPS J 11 T2245-501

[7] Matriano JA(2001)Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434-35

[8] Cormier M(2008)Parathyroid hormone treatment of osteoporosis Curr Opin Endocrinol Diab Obes 15 495-44

[9] Johnson J(2006)Patient treatment preferences for osteoporosis Arthritis Rheum 5 729-43

[10] Young WA(2007)Patient willingness to take teriparatide Patient Educ Couns 65 237-9